trastuzumab emtansine
1 clinical trial
1 product
16 abstracts
1 indication
Indication
Breast CancerAbstract
MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers.Org: US Medical Affairs Oncology,
Abstract
Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial.Org: West German Study Group, Moenchengladbach, Germany, Queen Mary University of London, London, United Kingdom, Medical School Brandenburg, Institute for Biometrics and Registry Research, Neuruppin, Neuruppin, Germany,
Abstract
The subgroup analysis by age and geriatric assessment in a phase III study comparison of trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study).Org: National Center for Global Health and Medicine, Shimane University Hospital, Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan,
Abstract
Safety run-in phase of the multi-epitope HER2 peptide vaccine in combination with trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy.Org: Mayo Clinic Florida, Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Mayo Clinic Department of Pediatric and Adolescent Medicine,
Abstract
Genomic landscape and therapeutic implications in advanced solid cancers: KOSMOS-II (KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors, KCSG AL-22-09).Org: Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, National Cancer Center Hospital East, Kashiwa, Japan, Goyang-Si, South Korea, Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy,
Abstract
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,
Abstract
Efficacy and toxicity of trastuzumab emtansine among patients with HER-2-positive metastatic breast cancer in Saudi Arabia.Org: King Faisal Specialist Hospital and Research Center, Alfaisal University College of Medicine, HCA Houston Healthcare Kingwood/University of Houston,
Clinical trial
A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative TherapyStatus: Active (not recruiting), Estimated PCD: 2018-07-25
Abstract
An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.Org: University Hospital Leuven, International Breast Cancer Centre (IBCC), Quironsalud Group, Aichi Cancer Center Hospital, Vall d’Hebron University Hospital/VHIO,
Abstract
Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases.Org: Duke Cancer Institute, Dana-Farber Cancer Institute, The Oncology Institute of Hope and Innovation, Suzhou Zanrong Pharma,
Abstract
Real-world treatment patterns in patients with HER2+ unresectable or metastatic breast cancer: Interim results from HER2 REAL Asia cohort.Org: National University Hospital, National Cheng Kung University Hospital, Queen Elizabeth Hospital, Seoul National University Hospital, Westmead Hospital,
Abstract
Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.Org: Memorial Sloan Kettering Cancer Center,
Abstract
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, NEXT Oncology - Virginia Cancer Specialists, University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute,
Abstract
AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,
Abstract
A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2+ unresectable locally advanced or metastatic breast cancer (aBC): Interim results of the ESTHER study (NCT02393924).Org: Roche Products Limited, Cmed Clinical Research Services, Leeds Institute of Medical Research at St James’s, Kent Oncology Centre, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,
Abstract
Efficacy of antibody-drug conjugates in breast cancer: A systematic review and meta-analysis of randomized clinical trials.Org: Saint Mary's and Saint Clare's Hospital, New York Medical College - Saint Michael's Medical Center, Schulich School of Medicine and Dentistry, BronxCare Health System, Dr. V.R.K. Women’s Medical College,
Product
Trastuzumab Emtansine